At Kyowa Kirin International, "Commitment to Life" is at our core. With over 500 people focused on this purpose we've become a highly successful and rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of innovative medicines for the treatment of unmet therapeutic needs.
Kyowa Kirin International plc is owned by Kyowa Kirin Co., Ltd. of Japan. Founded in 1949, Kyowa Kirin has a successful track record in Japan and is now expanding globally. Our areas of focus include rare diseases, haemato-oncology and intractable haematologic diseases and bone and mineral diseases, whilst leveraging innovative modalities for drug discovery and novel therapies in advanced antibody technology and haematopoietic stem cell gene therapies.
Headquartered in Galashiels, Scotland, Kyowa Kirin International maintains a significant presence across Europe and the Middle East through our network of commercial offices. This network ensures the agile and effective delivery of our products.
At Kyowa Kirin, we believe it is our people who have made the real difference to our success. Working together, our employees excel in getting results quickly and flawlessly. Our passion and energy around our core purpose of "commitment to life" sets us apart.
With our solid past and exciting future, Kyowa Kirin is looking for great people to join our team.
Supporting Patients
Kyowa Kirin launches the Time to Act global consensus statement in Cutaneous T-Cell Lymphoma (CTCL)
On Tuesday 14 May 2024, Kyowa Kirin proudly announced the publication of 'Time to Act: A Global Patient-Focused Consensus for Improving the Care of CTCL', which has been developed in collaboration with patient advocacy groups.
This consensus statement is the inaugural output of the CTCL Global Care Collaborative, a newly established group organized and funded by Kyowa Kirin. Its membership is comprised of patient advocacy groups from across the world and Kyowa Kirin.
The Collaborative is united by a shared mission to reduce the time to an accurate diagnosis and improve the quality of care and support for people living with CTCL.
To deliver on this mission, Time to Act calls on healthcare authorities, hospitals, and clinicians to undertake 12 specific actions to help enhance awareness, testing, diagnosis, care, and support for people impacted by CTCL.
Please take a few minutes to read through the full consensus statement, available in English and German.
KKI/INT/KKI/0931 May 2024